期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性心力衰竭的药物治疗 被引量：2

The chemotherapy of chronic heart failure
下载PDF
导出
摘要 本文结合对心力衰竭病理生理机制的认识 ,复习了慢性心衰的药物治疗方法。在传统治疗的基础上 ,血管紧张素转换酶抑制剂和 β受体阻滞剂的应用已成为常规。 The chemo therapy of chronic heart failure is reviewed based on the current understanding of pathophysiology of heart failure. Angiotensin converting enzyme inhibitors and β adrenergic receptor blockers have been used as a routine regime. Other novel agents targeting on the biological mechanism of heart failure have been developed.
作者 倪超 朱文玲
机构地区 中国协和医科大学中国医学科学院北京协和医院
出处 《基础医学与临床》 CSCD 北大核心 2002年第1期26-31,共6页 Basic and Clinical Medicine
基金 国家自然科学基金海外青年合作研究基金 (30 0 2 80 0 7)
关键词 心力衰竭 药物治疗 病理 利尿剂 heart failure pharmacological therapy
分类号 R541.6 [医药卫生—心血管疾病]
  • 相关文献

参考文献36

  • 1Packer M. How should physicians view heart failure? the philosophical and physiological evolution of three conceptual models of the disease[J]. Am J Cardiol, 1993, 71:3C-11C.
  • 2Pepper G, Lee RW. Sympathetic activation in heart failure and its treatment with β-blockade[J]. Arch Intern Med, 1999, 159:225-234.
  • 3Collucci WS. Molecular and cellular mechanisms of myocardial failure[J]. Am J Cardiol, 1997, 80:15L-25L.
  • 4Sabbah H, Sharov VG. Apoptosis in heart failure[J]. Prog Cardiovasc Dis, 1998, 40:549-562.
  • 5Remme WJ, Swedberg K. Guideline for the diagnosis and treatment of chronic heart failure[J]. Eur Heart J, 2001, 22:1527-1560.
  • 6Hunt HA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. A report of the American college of cardiology/American heart association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure)[J]. Circulation, 2001, 104:2996-3007.
  • 7The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure[J]. N Engl J Med, 1991, 325:293-302.
  • 8Pfeffer M, Braunwald E, Moy LA, et al, (on behalf of the SAVE Investigators). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial[J]. N Engl J Med,1992, 327:669-677.
  • 9Flather M, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. ACE- Inhibitor Myocardial Infarction Collaborative Group[J].Lancet, 1993, 342:821-828.
  • 10Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators[J]. Circulation, 1992, 86:431-438.

同被引文献26

  • 1[1]Watson R D,Gibbs C R,Lip G Y.Clinical features and complications[J].BMJ,2000,320(7229):236-239.
  • 2[2]Cleland J G,Khand A,Clark A.The heart failure epidemic:exactly how big is it[J]? Eur Heart J,2001,22(8):623-626.
  • 3[3]Francis G S,Goldsmith S R,Levine T B,et al.The neurohumoral axis in congestive heart failure[J].Ann Intern Med,1984,101(3):370-377.
  • 4[4]Cohn J N,Ferrari R,Sharpe N.Cardiac remodeling--concepts and clinical implications:a consensus paper from an international forum on cardiac remodeling.Behalf of an International Forum on Cardiac Remodeling[J].J Am Coll Cardiol,2000,35(3):569-582.
  • 5[5]Katz A M.Heart failure in 2001:a prophesy revisited[J].Am J Cardiol,2001,87(12):1383-1386.
  • 6[6]Pedersen O D,Bagger H,Kober L,et al.Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction[J].Circulation,1999,100(4):376-380.
  • 7[7]Witherow F N,Helmy A,Webb D J,et al.Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure[J].Circulation,2001,104(18):2177-2181.
  • 8[8]Pfeffer M A.Enhancing cardiac protection after myocardial infarction:rationale for newer clinical trials of angiotensin receptor blockers[J].Am Heart J,2000,139(1 Pt 2):S23-S28.
  • 9[9]Struthers A D.Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure[J]? Br J Clin pharmacol,1999,47(5):479-482.
  • 10[10]Zannad F,Alla F,Dousset B,et al.Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure[J].Circulation,2000,102(22):2700-2706.

引证文献2

二级引证文献5

基础医学与临床
2002年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部